Home / Themes / MedTech Long '24: Lab Research & Trials
MedTech Long '24: Lab Research & Trials
Last updated
Theme thesis · 2/5 sections · Tickers 1 with notes · 6 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThis basket targets contract research, diagnostics, and lab services companies poised to benefit from a cyclical rebound in biotech funding, a Trump-led push fo
Thesis
This basket targets contract research, diagnostics, and lab services companies poised to benefit from a cyclical rebound in biotech funding, a Trump-led push for domestic reshoring, and a renewed policy and AI-enabled focus on accelerating trials. These firms are critical infrastructure for biopharma innovation, increasingly insulated from China exposure and positioned for long-term demand growth from oncology, rare disease, and gene therapy trials.
Bull case
Biopharma trial volume is rebounding: Clinical activity, biotech funding, and lab demand are accelerating off 2023–24 cyclical lows, as evidenced by improved order books and commentary from CRL and FTRE.
Reshoring tailwinds are material: Trump's trade policy and bipartisan support for onshoring biotech supply chains are driving renewed investment into U.S.-based CROs/CDMOs like NOTV and FTRE.
AI and organoid adoption expands TAM: FDA's push to reduce animal testing via organoids and AI modeling directly boosts demand for proprietary platforms like those at TKNO, CRL, and NOTV, with existing infrastructure benefitting from transition latency
Bear case
Recession stalls clinical activity: A broader economic slowdown could pressure early-stage biotech funding and delay discretionary research contracts.
Regulatory overhaul disappoints: Policy momentum to replace animal testing with AI/organoids may stall due to validation challenges, delaying implementation timelines.
Large-cap clients internalize capacity: Big pharma may reintegrate clinical and manufacturing work in-house, pressuring margins for contract service providers.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| CRO/CDMO order book growth and bookings | Quarterly | Direct signal on funding trends, client activity, and biopharma outsourcing demand. | Google_Sheets |
| Clinical trial starts by phase and geography | Monthly | Measures demand for CROs, labs, and CDMOs; growth in Phase 1–3 trials = upside. | Google_Sheets |
| Biotech private capital raised (US vs. China) | Monthly/Quarterly | Indicates funding availability for future trial spend; onshoring trend confirmation. | Google_Sheets |
Constituents
- NOTVT3— Inotiv, Inc.
- CDMOT3· no notes yet
- CRLT3· no notes yet
- DGXT3· no notes yet
- FTRET3· no notes yet
- LHT3· no notes yet
- MRVIT3· no notes yet